Rep. Gilbert Ray Cisneros, Jr. Buys BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on May 11th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

BridgeBio Pharma Stock Performance

BBIO stock traded down $0.17 during midday trading on Thursday, hitting $67.23. 234,434 shares of the stock were exchanged, compared to its average volume of 2,769,256. The stock’s 50-day moving average price is $70.51 and its 200-day moving average price is $72.15. The stock has a market cap of $13.17 billion, a price-to-earnings ratio of -17.92 and a beta of 0.97. BridgeBio Pharma, Inc. has a fifty-two week low of $38.57 and a fifty-two week high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The company had revenue of $194.52 million during the quarter, compared to analysts’ expectations of $178.07 million. During the same period in the previous year, the company posted ($0.88) earnings per share. The business’s revenue was up 66.8% compared to the same quarter last year. Research analysts anticipate that BridgeBio Pharma, Inc. will post -2.32 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BBIO. Morgan Stanley lifted their price target on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the company an “overweight” rating in a research report on Thursday, May 28th. Barclays reaffirmed an “overweight” rating on shares of BridgeBio Pharma in a research report on Tuesday, March 10th. Truist Financial lifted their price target on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Finally, JPMorgan Chase & Co. lifted their price target on shares of BridgeBio Pharma from $89.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, March 10th. Twenty-three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $89.59.

Institutional Trading of BridgeBio Pharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd bought a new position in BridgeBio Pharma during the 3rd quarter valued at $31,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of BridgeBio Pharma during the third quarter worth $34,000. Jones Financial Companies Lllp bought a new position in BridgeBio Pharma during the first quarter valued at about $35,000. Huntington National Bank raised its holdings in BridgeBio Pharma by 111.7% during the third quarter. Huntington National Bank now owns 743 shares of the company’s stock valued at $39,000 after buying an additional 392 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in BridgeBio Pharma by 91.4% during the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after buying an additional 245 shares in the last quarter. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $67.90, for a total value of $2,716,000.00. Following the sale, the chief executive officer directly owned 575,686 shares of the company’s stock, valued at approximately $39,089,079.40. This trade represents a 6.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $67.15, for a total value of $671,500.00. Following the sale, the director directly owned 11,589 shares in the company, valued at approximately $778,201.35. This trade represents a 46.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 171,754 shares of company stock valued at $11,914,859 in the last three months. 14.23% of the stock is currently owned by corporate insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.